Vera Therapeutics Stock News

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted. The post Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Up

BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for p

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pa

BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pa

BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera"), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters'' option to purchase up to 748,959 additional shares. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $86.1 million. All of the shares were sold by Vera. J.P. Morgan, Cowen, and Evercore ISI acted as joint book-running managers for the offering. Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 9, 2022 and February 10, 2022. Copies of these Full story available on Benzinga.

Vera Therapeutics (VERA) prices its public offering of 4,993,067 shares at a price of $15.00 per share

Vera Therapeutics was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks

Vera Therapeutics (VERA) commenced a public offering to issue and sell 4M class A shares. VERA expects to grant the underwriters a 30-day option to purchase up to an additional 600K class

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics <> plans to begin a phase 3 trial of its lead product candidate atacicept in lupus nephritis ((LN)). The company said it received positive feedback from the U.S

Vera Therapeutics Inc - Class A (VERA) shares closed this week 20.9% lower than it did at the end of last week. The stock is currently down 20.9% year-to-date, up 83.8% over the past 12 months, and up 83.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $29.20 and as low as $20.28 this week.Shares closed 43.0% below its 52-week high and 87.1% above its 52-week low.Trading volume this week was 37.8% higher than the 10-day average and 14.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7913.4% The company's stock price performance over the past 12 months beats the peer average by -1058.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Vera Therapeutics Inc - Class A (VERA) shares closed today 10.8% lower than it did at the end of yesterday. The stock is currently down 20.9% year-to-date, up 83.8% over the past 12 months, and up 83.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $29.20 and as low as $20.28 this week.Shares closed 43.0% below its 52-week high and 87.1% above its 52-week low.Trading volume this week was 37.8% higher than the 10-day average and 14.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7913.4% The company's stock price performance over the past 12 months beats the peer average by -1058.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.